Raymond James & Associates Acquires 748 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Raymond James & Associates raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,592 shares of the medical instruments supplier’s stock after purchasing an additional 748 shares during the period. Raymond James & Associates owned 0.13% of LeMaitre Vascular worth $2,749,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co boosted its holdings in LeMaitre Vascular by 44.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after purchasing an additional 6,875 shares during the period. Quantbot Technologies LP increased its stake in LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after acquiring an additional 6,669 shares during the period. Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after acquiring an additional 38,303 shares in the last quarter. Quadrature Capital Ltd lifted its position in shares of LeMaitre Vascular by 129.4% in the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after acquiring an additional 12,654 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in shares of LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 1.5 %

LMAT stock opened at $96.35 on Tuesday. LeMaitre Vascular, Inc. has a twelve month low of $47.72 and a twelve month high of $101.67. The company has a market cap of $2.16 billion, a P/E ratio of 52.65, a PEG ratio of 2.32 and a beta of 0.89. The business has a fifty day moving average of $89.70 and a 200-day moving average of $83.49.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same period in the previous year, the business posted $0.33 EPS. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.86 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.97%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Oppenheimer restated an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price for the company. Finally, JMP Securities raised their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.57.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.